<DOC>
	<DOCNO>NCT00004188</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This randomized phase III trial study peripheral stem cell transplantation treat peripheral stem cell follow combination chemotherapy see well work compare peripheral stem cell transplantation untreated peripheral stem cell follow combination chemotherapy treat patient neuroblastoma .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare event-free survival patient newly diagnose high risk neuroblastoma ganglioneuroblastoma treat myeloablative consolidation chemotherapy autologous purge versus unpurged peripheral blood stem cell ( PBSC ) . - Compare time engraftment CD34 content tumor content reverse transcriptase polymerase chain reaction ( RT-PCR ) purge versus unpurged PBSC patient treat regimen . - Determine event-free survival patient treat dose intensive induction chemotherapy comprise cyclophosphamide , doxorubicin , vincristine alternate cisplatin etoposide . - Determine toxicity dose-intensive induction chemotherapy regimen patient . - Evaluate tumor resectability second look delay surgery , response ( complete response good partial response ) completion induction therapy , tumor content peripheral blood bone marrow , comparison historical data CCG-3891 induction therapy patient . Secondary - Compare toxicity myeloablative consolidation regimen use purge v unpurged PBSC patient . - Determine event-free survival predictable RT-PCR positivity stem cell , minimal residual disease bone marrow peripheral blood transplantation immunocytology , extent disease measure MIBG transplantation patient treat regimen . - Evaluate prognostic impact tumor biology event free survival patient treat regimen . - Determine incidence relapse primary site radiotherapy irradiate versus unirradiated metastatic site patient . - Assess toxicity tolerability maintenance therapy topotecan cyclophosphamide intensive induction therapy patient decline unable receive myeloablative therapy . - Determine health-related quality life patient treat regimen . - Compare late effect regimens growth , endocrine , pulmonary , cardiac function patient v general population standard . - Determine incidence second malignant neoplasms patient treat regimen . - Determine variability isotretinoin pharmacokinetics relationship pharmacogenomic parameter patient . - Correlate isotretinoin pharmacokinetics pharmacogenomic parameter and/or genetic variation isotretinoin metabolic enzyme event-free survival systemic toxicity patient . OUTLINE : This randomize study . Patients randomize one two treatment arm peripheral blood stem cell ( PBSC ) collection . All patient receive induction chemotherapy comprise cyclophosphamide IV 6 hour day 0 1 , doxorubicin IV vincristine IV continuously 72 hour day 0-2 , filgrastim ( G-CSF ) subcutaneously ( SC ) IV begin day 3 continue blood count recover course 1 , 2 , 4 , 6 . Treatment alternate course 3 5 comprise etoposide IV 2 hour day 0-2 , cisplatin IV 1 hour day 0-3 , G-CSF SC IV begin day 4 continue blood count recover . Induction chemotherapy repeat every 3 week blood count recover absence disease progression unacceptable toxicity . After course 2 3 induction chemotherapy , patient undergo PBSC collection , either purge unpurged , depend randomization . Patients continue daily G-CSF cell collection complete . - Arm I : Patients undergo unpurged PBSC collection target cell count reach . - Arm II : Patients undergo purge PBSC collection target cell count reach . Patients immunocytology positive PBSC undergo purge autologous bone marrow collection repeat purge unpurged PBSC collection depend individual patient characteristic . All patient undergo delayed surgical resection residual tumor course 5 induction chemotherapy . After induction therapy , patient achieve complete response , good partial response , partial response receive consolidation therapy comprise melphalan IV day -7 -5 follow carboplatin IV etoposide IV continuously day -7 -4 . Patients receive purge unpurged PBSC infusion purge autologous bone marrow transplantation day 0 follow G-CSF SC IV begin 4 hour completion transplantation continue blood count recover . Beginning day 66 , patient receive oral isotretinoin twice daily 14 day . Isotretinoin therapy repeat every 4 week 6 course . After completion consolidation ( least 28 day stem cell infusion ) , patient receive local radiotherapy daily 7 day . Patients undergo transplantation ineligible consolidation therapy receive maintenance therapy comprise cyclophosphamide IV 30 minute follow topotecan IV 30 minute day 0-4 . Patients receive G-CSF SC IV begin day 5 continue blood count recover . Maintenance therapy repeat every 3 week 3 course . After completion maintenance therapy , patient receive radiotherapy outline . Patients receive oral isotretinoin twice daily 14 day . Isotretinoin therapy repeat every 4 week 6 course . Quality life assess 1* 5 year . Patients follow every 3 month 1 year , every 6 month 4 year , annually thereafter disease progression . NOTE : * Patients 5 year age 1 year assess 5 year . PROJECTED ACCRUAL : A total 486 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose neuroblastoma OR ganglioneuroblastoma , and/or evidence clump tumor cell bone marrow elevate urinary catecholamine metabolite , meet 1 follow criterion : Age great 18 month stage IV disease , regardless biologic factor Age 1218 month stage IV disease meet one follow criterion : Any unfavorable biologic feature ( e.g. , MYCN amplification , unfavorable pathology , and/or DNA index = 1 ) Any biologic feature indeterminate , unsatisfactory , unknown At least 1 year old following : Stage IIa/IIb MYCN amplification ( &gt; 10 ) AND unfavorable pathology Stage III MYCN amplification ( &gt; 10 ) OR unfavorable pathology Stage I , II , IVS disease progression stage IV without interval chemotherapy No 3 week since progression Must enrol protocol CCGB973 , COGANBL00B1 , POG9047 Less 1 year old following : Stage III , IV , IVS disease MYCN amplification ( &gt; 10 ) Registration protocol COGANBL00B1 require within 14 day diagnosis PATIENT CHARACTERISTICS : Age : See Disease Characteristics 30 time diagnosis Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Inadequate hematopoiesis secondary bone marrow involvement &gt; 10 % tumor infiltration allow Hepatic : Bilirubin ≤ 1.5 mg/dL ALT ≤ 300 units/L Renal : Creatinine ≤ 1.5 mg/dL Creatinine clearance glomerular filtration rate ≥ 60 mL/min Cardiovascular : ECG normal Ejection fraction ≥ 55 % echocardiogram MUGA OR Fractional shorten ≥ 28 % echocardiogram Other : Able tolerate peripheral blood stem cell collection HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 1 month prior , , 1 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 1 prior course chemotherapy Intergroup low/intermediate risk neuroblastoma study ( P9641 , A3961 ) Endocrine therapy : Not specify Radiotherapy : Prior localize emergency radiotherapy sit lifethreatening functionthreatening disease allow Surgery : Not specify Other No prior systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>